BAY 43-9006, a multikinase inhibitor that targets Raf, prevents tumor cell proliferation in vitro and inhibits diverse human tumor xenografts in vivo. The mechanism of action of BAY 43-9006 remains incompletely defined. In the present study, the effects of BAY 43-9006 on the antiapoptotic Bcl-2 family member Mcl-1 were examined. Collectively, these findings demonstrate that drug-induced Mcl-1 downregulation contributes to the proapoptotic effects of BAY 43-9006.
Introduction
The Raf family of serine/threonine kinases, which consists of A-Raf, B-Raf and C-Raf, plays an important role in proliferative signaling in mammalian cells.
Recently, activating mutations of B-Raf have been reported in approximately 70% of malignant melanomas and in a smaller fraction of other cancer types (ovarian, thyroid, colon, lung) (Davies et al., 2002; Pollock and Meltzer, 2002; Cohen et al., 2003; Mercer and Pritchard, 2003; Singer et al., 2003; Tannapfel et al., 2003) . In melanoma cells expressing mutant B-Raf, constitutive extracellular signal-regulated kinase (ERK) activation is required for proliferation. In these cells, depletion of B-Raf by small inhibitory RNA (siRNA) inhibits ERK phosphorylation, DNA synthesis and continued cell survival, whereas depletion of A-RAF or C-RAF does not. Coupled with additional data (Wan et al., 2004) , these results suggest that B-Raf may be an important cancer therapeutic target (Dhillon et al., 2003; Karasarides et al., 2004) .
BAY 43-9006 is an orally bioavailable bisarylurea that has been developed as a multikinase inhibitor. It is a potent inhibitor of Raf kinases, with IC 50 values of 2, 25, and 38 nM against C-Raf, wild-type B-Raf, and mutant B-Raf in vitro under cell-free conditions (Wilhelm et al., 2004) . Anticancer activity has been observed in cancers that harbor Ras and B-raf mutations, as well as in cancers in which the Ras-ERK pathway is activated through overexpression of growth factor receptors, suggesting the potential use of this compound in a wide spectrum of cancers. Under cellfree conditions, BAY 43-9006 has also been shown to be a potent inhibitor of receptor tyrosine kinases that bind vascular endothelial growth factor (VEGFR-2, IC 50 ¼ 90 nM) and platelet-derived growth factor b (IC 50 ¼ 38 nM) (Wilhelm et al., 2004) , two molecules that are important mediators of tumor angiogenesis, as well as c-Kit, Flt-3, and p38. Thus, the anticancer activity of BAY 43-9006 is currently thought to be due to a dual mechanism of action of inhibiting tumor cell proliferation and tumor angiogenesis (Wilhelm et al., 2004) .
In clinical trials, the recommended phase II dose of 400 mg BAY 43-9006 twice daily results in a steady-state mean plasma concentration of approximately 10 mM (Strumberg et al., 2005) . Phase II trials of BAY 43-9006 have indicated clinical antitumor activity. In renal cell carcinoma, a X25% tumor shrinkage was documented in 40% of patients, with a median survival of 12.3 months (Ratain et al., 2004) . In spite of the identification of the targets of BAY 43-9006, the molecular events following inhibition of these targets in cancer cells remain unknown.
The antiapoptotic Bcl-2 family member Mcl-1 has been implicated in resistance to anticancer drugs in a number of settings (Craig, 2002) . For example, Mcl-1 upregulation occurs in 50% of acute leukemias at the time of recurrence (Kaufmann et al., 1998) . Likewise, Mcl-1 overexpression has been associated with a poor clinical response in chronic lymphocytic leukemia (CLL) (Kitada et al., 1998) . Additional studies have shown that Mcl-1 confers resistance to apoptosis induced by cytotoxic agents, c-myc overexpression and growth factor withdrawal in CLL cells (Moshynska et al., 2004) . More recently, Mcl-1 overexpression has been shown to mediate resistance to TRAIL-induced apoptosis in cholangiocarcinoma cell lines as well (Taniai et al., 2004) .
Recent data have suggested that Mcl-1 stability depends on ERK-mediated phosphorylation (Domina et al., 2000 (Domina et al., , 2004 Milella et al., 2001; Meng et al., 2003) . In view of these results, the objective of this study was to determine whether the apoptotic effects of BAY 43-9006 were mediated through Mcl-1 downregulation. We not only report here that Mcl-1 is selectively downregulated after BAY 43-9006 treatment in a wide variety of cancer cell lines, but also demonstrate that forced Mcl-1 overexpression protects cells from BAY 43-9006-induced apoptosis, whereas Mcl-1 downregulation by shRNA enhances sensitivity to BAY 43-9006. Based on these results, we describe strategies employing BAY 43-9006 to enhance the cytotoxicity of other proapoptotic agents.
Results

Effects of BAY 43-9006 on Mcl-1 expression
Based on previous studies demonstrating that inhibition of MEK1 can affect expression of Bcl-2 family members (Boucher et al., 2000; Milella et al., 2001; Meng et al., 2003) , the effect of BAY 43-9006 on expression levels of Bcl-2 family members and other antiapoptotic proteins in A549 cells was examined by immunoblotting. After a 24 h drug exposure, levels of Bcl-2, Bcl-x L , Bax, Bak, Bid and Bim did not change appreciably. Only Mcl-1 levels were decreased (Figure 1a ). To further explore BAY 43-9006-induced Mcl-1 downregulation, A549 cells were exposed for varying lengths of time as indicated in Figure 1b . Mcl-1 downregulation was noted as early as 3 h after addition of 5.0 mM BAY 43-9006 or 12 h after addition of 2.5 mM BAY 43-9006, indicating that Mcl-1 is selectively downregulated by BAY 43-9006 in a timeand dose-dependent manner.
To rule out the possibility that BAY 43-9006-induced Mcl-1 downregulation was cell line-specific, parallel studies were performed in additional transformed human cell lines. As was the case in A549 cells, exposure to (Wilhelm et al., 2004) . Previously published data also indicated that the MAPK pathway regulates Mcl-1 levels post-translationally (Domina et al., 2000 (Domina et al., , 2004 Milella et al., 2001; Meng et al., 2003) . 
Mcl-1 protects cells from BAY 43-9006-induced apoptosis
The preceding results suggest a model in which BAY 43-9006 induces apoptosis by causing Mcl-1 downregulation. If this model is correct, it leads to a number of predictions. (Figure 6c, d) , a finding also reflected in the increased cleavage of caspase 9 and PARP (Figure 6e ).
BAY 43-9006 synergistically enhances adaphostin-induced apoptosis
Since Mcl-1 is thought to protect cells from a variety of proapoptotic stimuli that activate the mitochondrial apoptotic pathway (Craig, 2002) , the observation that BAY 43-9006 downregulates Mcl-1 suggests that BAY 43-9006 should sensitize cells to other stimuli that activate this pathway. To test this possibility, we chose adaphostin, an agent that triggers apoptosis through the mitochondrial pathway (Svingen et al., 2000) by upregulating ROS Yu et al., 2004) , as a prototypic proapoptotic stimulus. K562 cells were exposed to BAY 43-9006 alone, adaphostin alone, or the combination. As indicated in Figure 7a and b, BAY 43-9006 dramatically enhanced the ability of adaphostin to induce apoptosis. When the data were analysed by the median effect method, the combination index was o1 over a wide concentration range, indicating a synergistic interaction between BAY 43-9006 and adaphostin.
Discussion
BAY 43-9006 is the first orally bioavailable multikinase inhibitor that targets Raf kinase to undergo clinical testing. The beneficial clinical effect of treatment with BAY 43-9006 has predominantly been disease stabilization in a wide variety of tumor types. This effect is consistent with the preclinical data that BAY 43-9006 exerts antitumor effects by both directly inhibiting tumor cell proliferation and by inhibiting tumor angiogenesis. Objective evidence of tumor shrinkage has been seen in renal cell carcinoma (Ahmad and , melanoma , hepatocellular (Strumberg et al., 2004) , pancreatic, and papillary thyroid carcinoma (Ratain et al., 2004) . The mechanism of tumor response to BAY 43-9006 is undefined but may include a proapoptotic component. Results of the present study not only highlight the importance of Mcl-1 downregulation in the proapoptotic effects of BAY 43-9006, but also suggest that BAY 43-9006 might (Milella et al., 2001; Meng et al., 2003; Domina et al., 2004) . Several additional observations, however, distinguish the effects of BAY 43-9006 from those of the MEK inhibitors. First, the effect of BAY 43-9006 on Mcl-1 levels is more rapid than that observed previously with MEK inhibitors (e.g., effects in Jurkat cells at 6 h in Figure 1c vs 24-48 h in Meng et al., 2003) . Second, the effect of BAY 43-9006 at these early time points is not reproduced by the MEK1/2 inhibitor U0126 (Figure 3a) . Third, BAY 43-9006 is able to diminish Mcl-1 under conditions that do not affect ERK phosphorylation (Figure 3a, c) .
While these observations seem to rule out the dependence of Mcl-1 downregulation on the MEK/ERK pathway, it is still possible that a Raf-dependent and MAPK-independent pathway might play a role. Alternatively, because BAY 43-9006 has significant inhibitory activity against several receptor tyrosine kinases involved in neo-vascularization and tumor progression, including VEGFR-2, VEGFR-3, PDGFRb, Flt-3, and c-Kit, it is possible that interruption of signaling downstream of one of these targets, but independent of Raf, contributes to the Mcl-1 downregulation observed in the present study. Consistent with this latter possibility, a recent study has demonstrated that Mcl-1 levels diminish due to enhanced protein turnover when Akt signaling is disrupted downstream of the interleukin-6 receptor (Kobayashi et al., 2005) . Since Mcl-1 is phosphorylated on a number of different residues in response to a variety of stimuli (Domina et al., 2000 (Domina et al., , 2004 Inoshita et al., 2002) , turnover of this short-lived antiapoptotic protein is likely subject to regulation by a number of different signaling pathways. To the extent that BAY 43-9006 inhibits multiple kinases, Mcl-1 downregulation might even reflect the ability of BAY 43-9006 to target more than one pathway affecting Mcl-1 stability. The present studies also demonstrated that BAY 43-9006 induces apoptosis in a wide variety of transformed cell lines. This result is consistent with that reported in melanoma cell lines (Karasarides et al., 2004) . Among the apoptotic changes observed after BAY 43-9006 treatment were mitochondrial release of cytochrome c and cleavage of caspases to their active fragments (Figure 4b and 6b) as well as apoptotic morphological changes. The observation that apoptotic changes only occur after treatment with BAY 43-9006 concentrations that downregulate Mcl-1 (cf. Figures 1 and 5) further highlights the importance of Mcl-1 downregulation in this process. Interestingly, this Mcl-1 downregulation occurs very rapidly (evident at 3 h), but apoptosis only becomes evident after 1 (Figures 4 and 7) to 4 days (Figure 5a) . A similar delay between Mcl-1 downregulation and subsequent cell death has previously been reported in murine lymphohematopoietic tissues following conditional deletion of the Mcl-1 gene in vivo (Opferman et al., 2003 (Opferman et al., , 2005 . Collectively, these observations raise the possibility that Mcl-1 downregulation contributes to apoptosis but might not be sufficient for apoptosis induction. Instead, it is possible that additional events (e.g., damage from endogenous ROS) serve as a trigger for apoptosis in cells in which Mcl-1 has been downregulated.
To test this hypothesis, cells were treated with adaphostin, an agent that has recently been shown to upregulate ROS Yu et al., 2004) . The observation that these two agents synergize ( Figure 7 ) is certainly consistent with the possibility that BAY 43-9006-induced Mcl-1 downregulation might sensitize cells to endogenous triggers of apoptosis. Moreover, these findings suggest that BAY 43-9006 might also sensitize cells to other agents that trigger apoptosis through the mitochondrial pathway.
In summary, the present studies have demonstrated that BAY 43-9006 induces apoptosis through selective destabilization and downregulation of Mcl-1. These observations simultaneously provide a potentially useful biomarker of BAY 43-9006 that can be explored in future clinical trials as well as a plausible explanation for the ability of this agent to shrink some tumors. Further preclinical and possible clinical studies are required to determine whether BAY 43-9006 would be efficacious in tumors in which Mcl-1 accumulation causes resistance to therapy, such as CLL, relapsed acute leukemia and cholangiocarcinoma. Likewise, further studies are required to determine whether the Mcl-1 downregulation translates into an ability of BAY 43-9006 to synergize with a broader range of chemotherapeutic agents. (Taniai et al., 2004) .
Materials and methods
Materials
Cell culture
Subconfluent, logarithmically growing cells were placed in sterile plastic T-flasks, allowed to adhere, supplemented with the designated drugs, and incubated in a humidified incubator with 5% CO 2 at 371C for various intervals as indicated.
Immunoblot analysis
Following drug treatment, cell lysates were prepared and subjected to immunoblot analysis using 30 mg of cellular protein as described previously (Yu et al., 2003) . The following primary antibodies were utilized at 1 : 1000 dilution unless otherwise indicated: rabbit polyclonal antibodies to caspase 9, 
Detection of apoptotic changes
Following drug treatment, the release of cytochrome c from the mitochondria was analysed by a selective digitonin permeabilization method as reported previously (Yu et al., 2003) . Changes in nuclear morphology were assessed after Wright-Giemsa or DAPI staining as described previously (Yu et al., 2003; Taniai et al., 2004) .
RT-PCR
After drug treatment, RNA was isolated using an RNeasyt mini kit (Qiagen, Valencia, CA, USA). One-twentieth of the cDNA product was used for each amplification reaction. Primers used were as follows. Mcl-1 forward primer 5 0 -CGGTAATCGGACTCAACCTC-3 0 , reverse primer 5 0 -CCTCCTTCTCCGTAGCCAA-3 0 . GAPDH forward primer 5 0 -GGCAAATTCCATGGCACCGTCAGG-3 0 , and reverse primer 5 0 -GGAGGCATTGCTGATGA-TCCTGAGG-3 0 . PCRs were performed using Expandt high-fidelity PCR reagents from Roche Applied Science following the supplier's instructions. The amplification was followed by 30 cycles with 951C hot start for 4 min, 951C for 30 s, 551C for 45 s, and 721C for 1 min. PCR products were electrophoresed on a 1% agarose gel containing 0.5 mg/ml EB (ethidium bromide) in 1 Â TAE buffer (30.7 mM Tris, 20 mM sodium acetate, and 1 mM EDTA), and visualized on a UV transilluminator.
Transient transfection
Constitutively active MEK1 (S218D/S222D) in pUSEamp (Clontech Laboratories) was subcloned in-frame into the pEGFP plasmid (Upstate Biotechnology) using standard techniques. The entire MEK1/GFP cDNA in the fusion construct was sequenced, and the reading frame was confirmed. Log-phase A549 cells were transfected with a pEGFP empty vector or a pEGFP/MEK1 fusion plasmid using Lipofectamine Plus (Invitrogen) following the supplier's instructions. After 24-h incubation, 50-60% of the cells displayed green fluorescence. The brightest 30-40% of the total cell population was isolated by fluorescence-activated cell sorting and analysed as described in the text.
Generation of a stably transfected cell line
K562 cells were transfected with pcDNA3.1 containing human full-length Mcl-1 cDNA (kindly provided by Ruth Craig, Dartmouth Medical School, Hanover, NH, USA) as described previously (Meng et al., 2003) . Stably transfected Mcl-1 clones were selected with 800 mg/L G418, cloned by limiting dilution, screened by immunoblotting, and propagated in medium supplemented with 500 mg/L G418.
Analysis of combined drug effects
The effect of combining BAY 43-9006 and adaphostin was analysed using the median effect method of Chou and Talalay (1984) using Calcusyn software (Biosoft, Oxford, UK) as reported previously (Adjei et al., 2001) .
Statistical analysis
All of the data were expressed as mean7s.d. from three individual experiments. Differences between groups were determined by using the Student's t-test for unpaired observations. Po0.05 was considered significant. Abbreviations ERK, extracellular signal-regulated kinase; CLL, chronic lymphocytic leukemia; FBS, heat-inactivated fetal bovine serum; GFP, green fluorescent protein; MEK, mitogenactivated and extracellular signal-regulated kinase; ROS, reactive oxygen species; shRNA, short hairpin RNA.
